Patents by Inventor Tristan REUILLON

Tristan REUILLON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS
    Publication number: 20240300936
    Abstract: This invention relates to compounds which are microtubule associated serine/threonine-like kinase (MASTL) inhibitors and the use of the compounds in the treatment of diseases and medical conditions mediated by MASTL, for example in the treatment of cancer and other target related diseases.
    Type: Application
    Filed: June 9, 2022
    Publication date: September 12, 2024
    Applicant: AVELOS THERAPEUTICS INC.
    Inventors: Ki Seon BAEK, Ja Heouk KHOO, Soongyu CHOI, Young Whan PARK, Simon WARD, Darren LE GRAND, Ryan WEST, Penelope TURNER, Samuele MARAMAI, Tristan REUILLON
  • MACROCYCLIC ETHER CONTAINING INDOLE DERIVATIVES AS INHIBITORS OF MCL-1
    Publication number: 20230250109
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
    Type: Application
    Filed: July 8, 2021
    Publication date: August 10, 2023
    Inventors: Benoît Christian Albert Ghislain DE BOECK, Petrus Jacobus Johannes Antonius BUIJNSTERS, Sofia FERRER CABRERA, Aldo PESCHIULLI, Tristan REUILLON, Frederik Jan Rita ROMBOUTS, Adriana-Ingrid VELTER
  • MACROCYCLIC INDOLE DERIVATIVES AS INHIBITORS OF MCL-1
    Publication number: 20230130109
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.
    Type: Application
    Filed: February 18, 2021
    Publication date: April 27, 2023
    Inventors: Frederik Jan Rita ROMBOUTS, Tristan REUILLON, Aldo PESCHIULLI, Adriana-Ingrid VELTER, Ann Marleen VOS
  • COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION
    Publication number: 20230000847
    Abstract: The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.
    Type: Application
    Filed: March 4, 2022
    Publication date: January 5, 2023
    Inventors: Simon WARD, Paul BESWICK, Lewis PENNICOTT, Tristan REUILLON, Irina CHUCKOWREE, Carolina VILLALONGA-BARBER, Roderick Alan PORTER
  • Compounds that modulates AMPA receptor function
    Patent number: 11298345
    Abstract: The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: April 12, 2022
    Assignee: University College Cardiff Consultants Limited
    Inventors: Simon Ward, Paul Beswick, Lewis Pennicott, Tristan Reuillon, Irina Chuckowree, Carolina Villalonga-Barber, Roderick Alan Porter
  • AMPA receptor potentiators
    Patent number: 11186567
    Abstract: The invention provides compounds of the formula (I): wherein R1 and R2 are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: November 30, 2021
    Assignee: University College Cardiff Consultants Limited
    Inventors: Simon Ward, Paul Beswick, Lewis Pennicott, Tristan Reuillon
  • AMPA RECEPTOR POTENTIATORS
    Publication number: 20210139463
    Abstract: The invention provides compounds of the formula (I): wherein R1 and R2 are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.
    Type: Application
    Filed: February 9, 2018
    Publication date: May 13, 2021
    Inventors: Simon Ward, Paul Beswick, Lewis Pennicott, Tristan Reuillon
  • COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION
    Publication number: 20210113539
    Abstract: The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.
    Type: Application
    Filed: March 1, 2019
    Publication date: April 22, 2021
    Inventors: Simon WARD, Paul BESWICK, Lewis PENNICOTT, Tristan REUILLON, Irina CHUCKOWREE, Carolina VILLALONGA-BARBER, Roderick Alan PORTER
  • Pyrrolcarboxamide derivatives for the inhibition of ERK5
    Patent number: 10344017
    Abstract: The invention provides compounds of formula (I) or a tautomer, stereoisomer, N-oxide, pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the prophylaxis or treatment of a disease state or condition mediated by ERK5, in particular cancers.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: July 9, 2019
    Inventors: Tristan Reuillon, Duncan Miller, Stephanie Myers, Lauren Molyneux, Celine Cano, Ian Hardcastle, Roger Griffin, Laurent Rigoreau, Bernard Golding, Martin Noble
  • PYRROLCARBOXAMIDE DERIVATIVES FOR THE INHIBITION OF ERK5
    Publication number: 20180170911
    Abstract: The invention provides compounds of formula (I) or a tautomer, stereoisomer, N-oxide, pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the prophylaxis or treatment of a disease state or condition mediated by ERK5, in particular cancers.
    Type: Application
    Filed: September 18, 2015
    Publication date: June 21, 2018
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Tristan REUILLON, Duncan MILLER, Stephanie MYERS, Lauren MOLYNEUX, Celine CANO, Ian HARDCASTLE, Roger GRIFFIN, Laurent RIGOREAU, Bernard GOLDING, Martin NOBLE